Trusted by pharmacists and other healthcare professionals for over 60 years,
AHFS® DI® is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.
AHFS Drug Information® 2021: the #1 most reliable drug and safety resource.
Trusted by pharmacists and other healthcare professionals for over 60 years,
AHFS® DI® is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. AHFS is the only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization. With expanded and revised content supported by more than 94,000 references and incorporating the advice of numerous subject matter experts, AHFS® DI® helps you protect your patients. Each edition includes additional online monographs, which are updated throughout the year, and can be found on the For Subscribers section of ahfsdruginformation.com. The password can be found in the preface of the printed edition.
2021 Updates Include:
- New and extensively updated drug information for management of COVID-19-infections based on current guidelines, including use of antiviral agents such as remdesivir and lopinavir/ritonavir, SARS-CoV-2-specific monoclonal antibodies (e.g., bamlanivimab), as well as use of supporting agents such as corticosteroids, immune globulin, nitric oxide, and tocilizumab
- Updated information on drugs commonly used for ICU sedation in critically ill patients with COVID-19, including propofol, dexmedetomidine, and midazolam and alternative drugs such as ketamine considered in potential drug shortage situations
- Revised information for influenza vaccines for the 2020-2021 season to address possible coinfection with COVID-19 and influenza
- Recommendations from current HIV guidelines for use of antiretroviral agents, including new fixed-combination antiretroviral products
- Revision of antiviral agents used to treat hepatitis C infections based on current guidelines
- Breakthroughs oncology drugs approved as part of the FDA’s accelerated approval program
- New oncology therapies for the treatment of cancers associated with activating gene mutations and oncogenic gene fusions
- Improved information on oncology off-label uses
- New information on non-oncology off-label uses (e.g., use of mycophenolate in lung transplantation)
- Latest safety updates based on MedWatch alerts (e.g., warning for cyclin-dependent kinase [CDK] inhibitors regarding interstitial lung disease/pneumonitis; risk of serious bowel problems with clozapine; serious, life-threatening, or fatal respiratory depression with gabapentin and pregabalin; stronger warning regarding risk of neuropsychiatric effects with montelukast)
- Expansion of the current guidance on making use of naloxone more widely available to high-risk individuals for opioid overdose
- Addition of new monograph for bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women
